Emergent BioSolutions Inc (NYSE:EBS)

21.34
BATS BZX Real-Time Price
As of 3:03pm ET
 +0.81 / +3.95%
Today’s Change
20.06
Today|||52-Week Range
55.35
-50.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$1.0B

Company Description

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Contact Information

Emergent BioSolutions, Inc.
400 Professional Drive
Gaithersburg Maryland 20879
P:(240) 631-3200
Investor Relations:
(240) 631-3280

Employees

Shareholders

Mutual fund holders50.65%
Other institutional33.61%
Individual stakeholders24.96%

Top Executives

Robert G. KramerPresident, Chief Executive Officer & Director
Adam Robert HaveyChief Operating Officer & EVP-Business Operations
Richard Scott LindahlChief Financial Officer, Treasurer & Executive VP
Sharon M. SolomonChief Information Officer & Senior Vice President
Christopher H. CabellChief Medical Officer & Head-Clinical Development